Lilly

4Q Revenues: $6.1 billion (+8%)

4Q Earnings: $1.5 billion (+33%)

FY Revenues: $22.3 billion (+4%)

FY Earnings: $8.3 billion (up from $3.2 billion FY18)

Comments: Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Emgality, Basaglar, and Cyramza, represented approximately 46% of total revenue.  Revenue in the U.S. increased 7% to $3.5 billion. Revenue outside the U.S. increased 10% to $2.6 billion. Trulicity sales were $1.2 billion in the quarter, up 31%. Talz sales were up 37% to $420 million. Jardiance sales were $268 million, up 39%. Verzenio sales were $179 million, up from $83 million 4Q18. Cyramza sales were up 11% to $245 million. Humalog sales were down 1% to $763 million. Alimta sales were down 5% to $530.7 million. Forteo sales were down 18% to $360.2 million and Cialis sales were down 44% to $197.8 million. The increase in earnings was primarily driven by higher operating income, partially offset by higher income taxes.